| Multiple Sclerosis |
1 |
1 |
| COVID-19 |
0 |
0.99 |
| Immunization |
0 |
0.65 |
| Monoclonal Antibody |
0 |
0.65 |
| COVID-19 Vaccine |
0 |
0.61 |
| Pennsylvania |
0 |
0.39 |
| Biologic Therapy |
0 |
0.35 |
| Antineoplastic Drug |
0 |
0.26 |
| Hospital |
0 |
0.26 |
| Cardiovascular disease |
0 |
0.13 |
| Disease-Modifying Therapy |
0 |
0.13 |
| Dorsum |
0 |
0.13 |
| Face |
0 |
0.13 |
| Isolation |
0 |
0.13 |
| Multiple Sclerosis Relapse |
0 |
0.13 |
| Multiple Sclerosis Risk |
0 |
0.13 |
| Pain |
0 |
0.13 |
| Pandemic |
0 |
0.13 |
| Pain Management |
0 |
0.11 |
| Back Pain |
0 |
0.09 |
| Cardiovascular Risk Management |
0 |
0.06 |
| Obesity |
0 |
0.06 |
| Vaccines |
0 |
0.06 |